MOUNTAIN VIEW, Calif., Feb. 25, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investment conferences during the month of March. The conference presentation schedule is as follows:Citi's 2011 Global Health Care ConferenceMarch 1, 2011 at 4:00 p.m. ETHilton New York Hotel, New York, NYCowen and Company 31st Annual Health Care ConferenceMarch 8, 2011 at 8:45 a.m. ETThe Boston Marriott Copley Place, Boston, MAROTH Capital Partners 23rd Annual OC Growth Stock ConferenceMarch 15, 2011 at 11:30 a.m. PTRitz-Carlton, Laguna Niguel, CAA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved